Table 3.
Prognostic factor | p-value | Hazard Ratio | 95% Confidence Interval |
Local Control | |||
Stage grouping (III vs IV) | 0.013 | 1.816 | 1.134 – 2.908 |
Primary site (oral vs non-oral) | 0.001 | 0.648 | 0.497 – 0.845 |
No of CT cycles (less vs more) | 0.038 | 0.643 | 0.424 – 0.977 |
Loco-regional Control | |||
Stage grouping (III vs IV) | 0.000 | 2.406 | 1.551 – 3.734 |
No of CT cycles (less vs more) | 0.014 | 0.627 | 0.432 – 0.909 |
Disease Free Survival | |||
Stage grouping (III vs IV) | 0.000 | 2.640 | 1.707 – 4.081 |
No of CT cycles (less vs more) | 0.016 | 0.642 | 0.447 – 0.922 |